Executive Summary
Motorola Solutions and STA Group settled their IPR dispute over Patent 9,319,852, leading to a joint motion that terminated the proceeding. The Board granted the motion and ordered the settlement agreements to be kept confidential.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Motorola Solutions, Inc. vs STA Group, LLC is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Light & Wonder, Inc. et al.vsEvolution Malta Limited
The PTAB granted institution of IPR for Light & Wonder against Evolution Malta, finding a reasonable likelihood that Kido anticipates claims related to roulette wagering systems. The Board adopted a broad definition of 'payout' including progressive jackpots.
Amazon.com, Inc. et al.vsAudio Pod IP, LLC
Amazon and its affiliates have filed a Request for Director Review seeking reversal of a discretionary denial that applied a new six‑year settled‑expectations standard to block their IPR petition against Audio Pod IP’s patent. They argue the standard violates the AIA, the APA, and due‑process rights. The Board has not yet ruled on the merits.
CISCO SYSTEMS, INC. et al.vsInfoExpress Inc.
CISCO Systems and FORTINET successfully instituted an IPR against InfoExpress Inc.'s patent, finding a reasonable likelihood of obviousness over Krantz and Herrmann. The Board agreed that combining network authentication (Krantz) with policy enforcement (Herrmann) would teach the claimed method for auditing devices.
Arm LimitedvsICPillar LLC
Arm Limited successfully secured institution for its IPR challenge against ICPillar LLC's patent 9367657, challenging claims based on obviousness over Banerjee and Rompaey/CoWare. The Board granted institution after the Petitioner mitigated concerns regarding parallel litigation in District Court.
Merck Sharp & Dohme LLCvsHalozyme, Inc. et al.
Merck challenges Halozyme’s request for Director review after the PTAB instituted a post‑grant review of U.S. Patent 12,018,298 covering modified PH20 polypeptides. Merck argues the eligibility and claim‑construction issues are meritless and that the Fintiv factors favor institution.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.